Evidence map›Paper›PMID 40485996›Full record

ArticleJHLT open2025

Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist.

Ali Ataya, James C Coons, Natalie Patzlaff, Meredith Broderick, Scott Seaman, Namita Sood, M Patricia George, Murali M Chakinala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ali AtayaDivision of Pulmonary and Critical Care Medicine, University of Florida, 1549 Gale Lemerand Drive, Gainesville, FL 32610-3008.
James C CoonsUniversity of Pittsburgh School of Pharmacy, 200 Lothrop Street, Pittsburgh, PA, 15213.
Natalie PatzlaffUnited Therapeutics Corporation, Research Triangle Park, 55 TW Alexader Dr. PO BOX 14186, Durham, NC, 27709.
Meredith BroderickUnited Therapeutics Corporation, Research Triangle Park, 55 TW Alexader Dr. PO BOX 14186, Durham, NC, 27709.
Scott SeamanUnited Therapeutics Corporation, Research Triangle Park, 55 TW Alexader Dr. PO BOX 14186, Durham, NC, 27709.
Namita SoodUniversity of California-Davis, 4150 V Street, PSSB Suite 3400, Sacramento, CA 95816.
M Patricia GeorgeNational Jewish Hospital, 1400 Jackson Street, J231, Denver, CO 80206.
Murali M ChakinalaDivision of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ralinepag is an oral, potent, highly selective prostacyclin receptor agonist and is in development for pulmonary arterial hypertension. Ralinepag was formulated as an immediate-release (IR) capsule, later modified to an extended-release (XR) tablet to optimize administration for once-daily dosing. Methods: This phase I study evaluated the pharmacokinetic (PK) profile and relative bioavailability of ralinepag XR. There were two cohorts of healthy participants ( Results: The ralinepag XR formulation showed a reduced maximum observed concentration (C Conclusion: Ralinepag XR has a half-life suitable for once-daily dosing. The reduced C

Indexed as

HypertensionProstaglandin/agonistsPulmonaryarterial hypertensionPulmonary/drug therapyRalinepagReceptors

Identifiers

PMID40485996
PMCPMC12143825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.